Temsirolimus as Second-line Therapy in HCC

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by University of Tennessee Cancer Institute.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
University of Tennessee Cancer Institute
ClinicalTrials.gov Identifier:
NCT01567930
First received: February 1, 2012
Last updated: December 13, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2013
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)